Acumen Pharmaceuticals, Inc. Common Stock
ABOS
ABOS: Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believe to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.
moreShow ABOS Financials
Recent trades of ABOS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ABOS's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 Apr. 26, 2016
-
Patent Title: Antibodies, kit and method for detecting amyloid beta oligomers Apr. 12, 2016
-
Patent Title: Addl receptor polypeptides, polynucleotides and host cells for recombinant production Dec. 22, 2015
-
Patent Title: Antibodies, kit and method for detecting amyloid beta oligomers Nov. 03, 2015
-
Patent Title: Methods of modifying amyloid β oligomers using non-peptidic compounds Apr. 14, 2015
-
Patent Title: Methods of restoring cognitive ability using non-peptidic compounds Feb. 24, 2015
-
Patent Title: Compositions and methods for the enhancement of soluble amyloid beta oligomer (addl) uptake and clearance Jun. 21, 2011
Federal grants, loans, and purchases
Followers on ABOS's company Twitter account
Number of mentions of ABOS in WallStreetBets Daily Discussion
Recent insights relating to ABOS
Recent picks made for ABOS stock on CNBC
ETFs with the largest estimated holdings in ABOS
Flights by private jets registered to ABOS